Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson B Rodrigues

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Journal of Affective Disorders|August 9, 2023
Corrigendum to "Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in major depressive disorder" [J. Affect. Disord.. 238, 2018, pages 228-232]Danielle S Cha, Nicole E Carmona, Nelson B Rodrigues, et al.
Infectious Diseases (London, England)|March 14, 2022
Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for researchFelicia Ceban, Alexia Leber, Muhammad Youshay Jawad, et al.
Journal of Affective Disorders|June 11, 2018
Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive DisorderDanielle S Cha, Nicole E Carmona, Nelson B Rodrigues, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2020
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.
Psychiatry Research|November 19, 2021
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effectsTuyen T Le, Joshua D Di Vincenzo, Kayla M Teopiz, et al.
Brain, Behavior, and Immunity|January 1, 2022
Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysisFelicia Ceban, Susan Ling, Leanna M W Lui, et al.
CNS Drugs|August 7, 2021
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood DisordersFelicia Ceban, Joshua D Rosenblat, Kevin Kratiuk, et al.
Journal of Affective Disorders|June 26, 2021
Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot studyRoger S McIntyre, Yena Lee, Nelson B Rodrigues, et al.
Journal of Affective Disorders|July 16, 2020
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of ExcellenceRoger S McIntyre, Nelson B Rodrigues, Yena Lee, et al.
Journal of Affective Disorders|September 3, 2020
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysisRoger S McIntyre, Isabelle P Carvalho, Leanna M W Lui, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal of Affective Disorders|August 9, 2023
Corrigendum to "Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in major depressive disorder" [J. Affect. Disord.. 238, 2018, pages 228-232]Danielle S Cha, Nicole E Carmona, Nelson B Rodrigues, et al.
Infectious Diseases (London, England)|March 14, 2022
Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for researchFelicia Ceban, Alexia Leber, Muhammad Youshay Jawad, et al.
Journal of Affective Disorders|June 11, 2018
Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive DisorderDanielle S Cha, Nicole E Carmona, Nelson B Rodrigues, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2020
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.
Psychiatry Research|November 19, 2021
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effectsTuyen T Le, Joshua D Di Vincenzo, Kayla M Teopiz, et al.
Brain, Behavior, and Immunity|January 1, 2022
Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysisFelicia Ceban, Susan Ling, Leanna M W Lui, et al.
CNS Drugs|August 7, 2021
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood DisordersFelicia Ceban, Joshua D Rosenblat, Kevin Kratiuk, et al.
Journal of Affective Disorders|June 26, 2021
Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot studyRoger S McIntyre, Yena Lee, Nelson B Rodrigues, et al.
Journal of Affective Disorders|July 16, 2020
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of ExcellenceRoger S McIntyre, Nelson B Rodrigues, Yena Lee, et al.
Journal of Affective Disorders|September 3, 2020
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysisRoger S McIntyre, Isabelle P Carvalho, Leanna M W Lui, et al.
Pageof 7